person · Reporting owner

DeFord John A

Disclosed activity across 5 companies

Tapewire entity: 27392
SEC CIK: 0001403373

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
GLOBUS MEDICAL INCGMED · Entity 3496	Director	January 21, 2026	January 23, 2026
MARAVAI LIFESCIENCES HOLDINGS, INC.MRVI · Entity 4291	Director	May 26, 2026	May 28, 2026
NORDSON CORPNDSN · Entity 30	Director	July 31, 2026	August 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GLOBUS MEDICAL INC

Report date January 21, 2026 · Filed January 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy Class A Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $94.15 · Expires 2036-01-21	Direct	15,000	Reported balance After 2026-01-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-21 · Grant · Acquired 15,000 · Balance 15,000 F1: These options were granted on January 21, 2026, and will vest on January 1, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: These options were granted on January 21, 2026, and will vest on January 1, 2027.

MARAVAI LIFESCIENCES HOLDINGS, INC.

Report date May 26, 2026 · Filed May 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	205,478	Reported balance After 2026-05-26 transaction · row 1 1 source row Row 1 · 2026-05-26 · Grant · Acquired 46,293 · Balance 205,478 F1: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

NORDSON CORP

Report date July 31, 2026 · Filed August 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
NDSNSEC Table I · non-derivative	Direct	5,902	Reported balance After 2026-07-31 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-07-31 · Grant · Acquired 84 · Balance 5,902 F1: Pursuant to the terms of the Company's Directors' Deferred Compensation Sub-Plan, the reporting person elected to defer his quarterly cash retainer payment into Stock Equivalent Units. At the time of distribution, stock equivalent units convert to common shares on a one-for-one basis F2: The total holdings include 16 Stock Equivalent Units and/or Restricted Share Units accrued from dividend payments pursuant to the Company's Stock Incentive and Award Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Company's Directors' Deferred Compensation Sub-Plan, the reporting person elected to defer his quarterly cash retainer payment into Stock Equivalent Units. At the time of distribution, stock equivalent units convert to common shares on a one-for-one basis

F2: The total holdings include 16 Stock Equivalent Units and/or Restricted Share Units accrued from dividend payments pursuant to the Company's Stock Incentive and Award Plan.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BARD C R INC /NJ/

Report date December 29, 2017 · Filed January 03, 2018

Section 16 reporting ended · disclosed 2018-01-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	30,707.2316	Reported balance After 2017-12-29 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-12-29 · Grant · Acquired 13,918 · Balance 30,707.2316 F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). All of the transactions reported in this Form 4 occurred simultaneously upon the closing of the Merger. F2: Includes 13,918 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units.
Common StockSEC Table I · non-derivative	Direct	35,982.2316	Reported balance After 2017-12-29 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2017-12-29 · Grant · Acquired 5,275 · Balance 35,982.2316 F3: Includes 5,275 Bard restricted stock units deemed acquired upon satisfaction of performance goals that were considered achieved upon the closing of the Merger.
Common StockSEC Table I · non-derivative	Direct	35,295	Reported balance After 2017-12-29 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2017-12-29 · Disposition to issuer · Disposed 687.2316 · Balance 35,295 F4: Includes 687.3216 shares of Bard common stock that, upon the closing of the Merger, were cancelled and converted into the right to receive the Merger Consideration.
Common StockSEC Table I · non-derivative	Direct	27,537	Reported balance After 2017-12-29 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2017-12-29 · Disposition to issuer · Disposed 7,758 · Balance 27,537 F5: Includes 7,758 Bard restricted stock units that, upon the closing of the Merger, were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent adjusted BD restricted stock units.
Common StockSEC Table I · non-derivative	Direct	13,918	Reported balance After 2017-12-29 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2017-12-29 · Disposition to issuer · Disposed 13,619 · Balance 13,918 F6: Includes 13,619 shares of restricted stock units acquired through deferral of compensation under Bard's Management Stock Purchase Program ("MSPP"). In accordance with the Merger Agreement (i) each Bard MSPP Unit that by its terms vested and/or became payable at the closing of the Merger was cancelled and converted into, with respect to each share of Bard common stock underlying such Bard MSPP Unit, the right to receive the Merger Consideration; and (ii) each Bard MSPP Unit that did not, by its terms, become payable at the closing of the Merger was assumed and converted in accordance with the exchange ratio set forth in the Merger Agreement into an equivalent adjusted BD MSPP Unit.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-12-29 transaction · row 6 Account or security details depend on footnotes; rows are not merged. 1 source row Row 6 · 2017-12-29 · Disposition to issuer · Disposed 13,918 · Balance 0 F2: Includes 13,918 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units.
Common StockSEC Table I · non-derivative	Indirect401(k) Plan	0	Reported balance After 2017-12-29 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2017-12-29 · Disposition to issuer · Disposed 83.82 · Balance 0 F7: Includes 83.82 shares of Bard common stock held through the Bard 401(k) Plan that were disposed of upon the closing of the Merger.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $186.43 · Expires 2025-12-09	Direct	0	Reported balance After 2017-12-29 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-12-29 · Disposition to issuer · Disposed 6,586 · Balance 0 F8: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $168.87 · Expires 2024-12-10	Direct	0	Reported balance After 2017-12-29 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-12-29 · Disposition to issuer · Disposed 3,768 · Balance 0 F8: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $219.56 · Expires 2026-12-14	Direct	0	Reported balance After 2017-12-29 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2017-12-29 · Disposition to issuer · Disposed 8,658 · Balance 0 F8: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). All of the transactions reported in this Form 4 occurred simultaneously upon the closing of the Merger.

F2: Includes 13,918 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units.

F3: Includes 5,275 Bard restricted stock units deemed acquired upon satisfaction of performance goals that were considered achieved upon the closing of the Merger.

F4: Includes 687.3216 shares of Bard common stock that, upon the closing of the Merger, were cancelled and converted into the right to receive the Merger Consideration.

F5: Includes 7,758 Bard restricted stock units that, upon the closing of the Merger, were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent adjusted BD restricted stock units.

F6: Includes 13,619 shares of restricted stock units acquired through deferral of compensation under Bard's Management Stock Purchase Program ("MSPP"). In accordance with the Merger Agreement (i) each Bard MSPP Unit that by its terms vested and/or became payable at the closing of the Merger was cancelled and converted into, with respect to each share of Bard common stock underlying such Bard MSPP Unit, the right to receive the Merger Consideration; and (ii) each Bard MSPP Unit that did not, by its terms, become payable at the closing of the Merger was assumed and converted in accordance with the exchange ratio set forth in the Merger Agreement into an equivalent adjusted BD MSPP Unit.

F7: Includes 83.82 shares of Bard common stock held through the Bard 401(k) Plan that were disposed of upon the closing of the Merger.

F8: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.

NUVASIVE INC

Report date September 01, 2023 · Filed September 05, 2023

Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-09-01 · Disposition to issuer · Disposed 563 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-09-01 · Disposition to issuer · Disposed 3,230 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-09-01 · Disposition to issuer · Disposed 2,577 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-09-01 · Disposition to issuer · Disposed 3,095 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-09-01 · Disposition to issuer · Disposed 2,702 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-09-01 · Disposition to issuer · Disposed 4,816 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
Restricted StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-09-01 · Disposition to issuer · Disposed 3,788 · Balance 0 F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

Filing footnotes · ownership attribution and instrument terms

F1: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 29, 2017 Filed Jan 3, 2018 20:18 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Disposition to issuerCommon Stock	83.82	$0.00	$0.00	Disclosure SEC source: 0001225208-18-000502 · doc4.xml · nonDerivative · entry 7 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Plan Disclosed balance after: 0 F7 · price: Includes 83.82 shares of Bard common stock held through the Bard 401(k) Plan that were disposed of upon the closing of the Merger. Read SEC document
December 29, 2017 Filed Jan 3, 2018 20:18 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Disposition to issuerCommon Stock	13,918	$0.00	$0.00	Disclosure SEC source: 0001225208-18-000502 · doc4.xml · nonDerivative · entry 6 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Includes 13,918 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units. Read SEC document
December 29, 2017 Filed Jan 3, 2018 20:18 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Disposition to issuerCommon Stock	13,619	$0.00	$0.00	Disclosure SEC source: 0001225208-18-000502 · doc4.xml · nonDerivative · entry 5 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,918 F6 · price: Includes 13,619 shares of restricted stock units acquired through deferral of compensation under Bard's Management Stock Purchase Program ("MSPP"). In accordance with the Merger Agreement (i) each Bard MSPP Unit that by its terms vested and/or became payable at the closing of the Merger was cancelled and converted into, with respect to each share of Bard common stock underlying such Bard MSPP Unit, the right to receive the Merger Consideration; and (ii) each Bard MSPP Unit that did not, by its terms, become payable at the closing of the Merger was assumed and converted in accordance with the exchange ratio set forth in the Merger Agreement into an equivalent adjusted BD MSPP Unit. Read SEC document
December 29, 2017 Filed Jan 3, 2018 20:18 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Disposition to issuerCommon Stock	7,758	$0.00	$0.00	Disclosure SEC source: 0001225208-18-000502 · doc4.xml · nonDerivative · entry 4 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,537 F5 · price: Includes 7,758 Bard restricted stock units that, upon the closing of the Merger, were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent adjusted BD restricted stock units. Read SEC document
December 29, 2017 Filed Jan 3, 2018 20:18 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Disposition to issuerCommon Stock	687.2316	$0.00	$0.00	Disclosure SEC source: 0001225208-18-000502 · doc4.xml · nonDerivative · entry 3 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,295 F4 · price: Includes 687.3216 shares of Bard common stock that, upon the closing of the Merger, were cancelled and converted into the right to receive the Merger Consideration. Read SEC document
December 29, 2017 Filed Jan 3, 2018 20:18 UTC	BARD C R INC /NJ/ BCR · Entity 170698	GrantCommon Stock	5,275	$0.00	$0.00	Disclosure SEC source: 0001225208-18-000502 · doc4.xml · nonDerivative · entry 2 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,982.2316 F3 · price: Includes 5,275 Bard restricted stock units deemed acquired upon satisfaction of performance goals that were considered achieved upon the closing of the Merger. Read SEC document
December 29, 2017 Filed Jan 3, 2018 20:18 UTC	BARD C R INC /NJ/ BCR · Entity 170698	GrantCommon Stock	13,918	$0.00	$0.00	Disclosure SEC source: 0001225208-18-000502 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,707.2316 F1 · security: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). All of the transactions reported in this Form 4 occurred simultaneously upon the closing of the Merger. F2 · price: Includes 13,918 shares of Bard common stock deemed acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of Bard (as amended and restated) ("PLTIP"). In accordance with the Merger Agreement, these PLTIP units were cancelled in connection with the Merger and converted in accordance with the exchange ratio set forth in the Merger Agreement into equivalent BD PLTIP units. Read SEC document
December 20, 2017 Filed Dec 22, 2017 14:57 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionOption (Right to Buy) · Derivative	2,886	$0.00 Strike: $219.56	$0.00	Disclosure SEC source: 0001225208-17-019019 · doc4.xml · derivative · entry 11 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,658 Underlying: Common Stock · 2,886 shares Expires 2026-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F10 · derivative.exercise_date: Of this option grant 2,886 options vested on December 14, 2017 and the remaining options vest in three annual installments beginning on December 14, 2018. Read SEC document
December 20, 2017 Filed Dec 22, 2017 14:57 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionOption (Right to Buy) · Derivative	4,161	$0.00 Strike: $136.37	$0.00	Disclosure SEC source: 0001225208-17-019019 · doc4.xml · derivative · entry 10 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,161 shares Expires 2023-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F9 · derivative.exercise_date: Options vested on December 11, 2017. Read SEC document
December 20, 2017 Filed Dec 22, 2017 14:57 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionOption (Right to Buy) · Derivative	3,767	$0.00 Strike: $168.87	$0.00	Disclosure SEC source: 0001225208-17-019019 · doc4.xml · derivative · entry 9 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,768 Underlying: Common Stock · 3,767 shares Expires 2024-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F8 · derivative.exercise_date: Of this option grant 3,767 options vested on December 10, 2017 and the remaining options vest on December 10, 2018. Read SEC document
December 20, 2017 Filed Dec 22, 2017 14:57 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionOption (Right to Buy) · Derivative	3,293	$0.00 Strike: $186.43	$0.00	Disclosure SEC source: 0001225208-17-019019 · doc4.xml · derivative · entry 8 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,586 Underlying: Common Stock · 3,293 shares Expires 2025-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F7 · derivative.exercise_date: Of this option grant 3,293 options vested on December 9, 2017 and the remaining options vest in two annual installments beginning on December 9, 2018. Read SEC document
December 20, 2017 Filed Dec 22, 2017 14:57 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	13,207	$333.43	$4,403,664.16	Disclosure SEC source: 0001225208-17-019019 · doc4.xml · nonDerivative · entry 6 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,789.2316 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F4 · price: Represents the weighted average sales price for price increments ranging from $332.96 to $333.95. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
December 20, 2017 Filed Dec 22, 2017 14:57 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	900	$334.12	$300,707.01	Disclosure SEC source: 0001225208-17-019019 · doc4.xml · nonDerivative · entry 5 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,996.2316 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F3 · price: Represents the weighted average sales price for price increments ranging from $333.97 to $334.30. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
December 20, 2017 Filed Dec 22, 2017 14:57 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionCommon Stock	2,886	$219.56	$633,635.73	Disclosure SEC source: 0001225208-17-019019 · doc4.xml · nonDerivative · entry 4 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,896.2316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. Read SEC document
December 20, 2017 Filed Dec 22, 2017 14:57 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionCommon Stock	3,293	$186.43	$613,897.53	Disclosure SEC source: 0001225208-17-019019 · doc4.xml · nonDerivative · entry 3 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,010.2316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. Read SEC document
December 20, 2017 Filed Dec 22, 2017 14:57 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionCommon Stock	3,767	$168.87	$636,114.46	Disclosure SEC source: 0001225208-17-019019 · doc4.xml · nonDerivative · entry 2 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,717.2316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. Read SEC document
December 20, 2017 Filed Dec 22, 2017 14:57 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionCommon Stock	4,161	$136.37	$567,435.57	Disclosure SEC source: 0001225208-17-019019 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,950.2316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F2 · balance_after: Includes 0.0887 shares acquired under the Company's Dividend Reinvestment Plan from February 4, 2017 to August 4, 2017. Includes 0.0020 shares acquired under the Company's Employee Stock Purchase Plan from February 7, 2017 to August 7, 2017. Read SEC document
February 14, 2017 Filed Feb 15, 2017 16:58 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	2,788	$240.51	$670,551.64	Disclosure SEC source: 0001225208-17-003412 · doc4.xml · nonDerivative · entry 3 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,530.1409 F3 · kind: Sales are pursuant to a previously disclosed 10b5-1 plan. F4 · price: Represents the weighted average sales price for price increments ranging from $240.33 to $240.85. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
February 13, 2017 Filed Feb 14, 2017 15:20 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	469	$240.07	$112,593.81	Disclosure SEC source: 0001225208-17-003182 · doc4.xml · nonDerivative · entry 2 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,662.1409 F3 · kind: Sales are pursuant to a previously disclosed 10b5-1 plan. F4 · price: Represents the weighted average sales price for price increments ranging from $240.05 to $240.10. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
February 13, 2017 Filed Feb 15, 2017 16:58 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Tax withholdingCommon Stock	1,897	$240.47	$456,171.59	Disclosure SEC source: 0001225208-17-003412 · doc4.xml · nonDerivative · entry 2 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,318.1409 F2 · kind: Shares withheld to pay taxes upon vesting of restricted stock units acquired through deferral of compensation under the Company's Management Stock Purchase Program. Read SEC document
February 13, 2017 Filed Feb 15, 2017 16:58 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Tax withholdingCommon Stock	447	$240.47	$107,490.09	Disclosure SEC source: 0001225208-17-003412 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,684.1409 F1 · kind: Shares withheld to pay taxes upon vesting of restricted stock units granted under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). Read SEC document
February 10, 2017 Filed Feb 14, 2017 15:20 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Tax withholdingCommon Stock	417	$239.93	$100,048.73	Disclosure SEC source: 0001225208-17-003182 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,131.1409 F1 · kind: Shares withheld to pay taxes upon vesting of restricted stock units granted under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F2 · balance_after: Includes 0.0583 shares acquired under the Company's Dividend Reinvestment Plan from November 5, 2016 to February 3, 2017. Read SEC document
February 09, 2017 Filed Feb 10, 2017 18:23 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	5,816	$239.58	$1,393,386.81	Disclosure SEC source: 0001225208-17-002837 · doc4.xml · nonDerivative · entry 6 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,548.0826 F6 · kind: Sales are pursuant to a previously disclosed 10b5-1 plan. F7 · price: Represents the weighted average sales price for price increments ranging from $239.49 to $239.83. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
February 08, 2017 Filed Feb 10, 2017 18:23 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Tax withholdingCommon Stock	4,004	$236.68	$947,666.72	Disclosure SEC source: 0001225208-17-002837 · doc4.xml · nonDerivative · entry 5 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,364.0826 F5 · kind: Shares withheld to pay taxes upon vesting of performance-based restricted stock units granted under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). Read SEC document
February 08, 2017 Filed Feb 10, 2017 18:23 UTC	BARD C R INC /NJ/ BCR · Entity 170698	GrantCommon Stock	703	$164.84	$115,884.63	Disclosure SEC source: 0001225208-17-002837 · doc4.xml · nonDerivative · entry 4 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,368.0826 F4 · kind: Restricted stock units acquired through deferral of compensation under the Company's Management Stock Purchase Program. Read SEC document
February 08, 2017 Filed Feb 10, 2017 18:23 UTC	BARD C R INC /NJ/ BCR · Entity 170698	GrantCommon Stock	1,641	$235.49	$386,439.09	Disclosure SEC source: 0001225208-17-002837 · doc4.xml · nonDerivative · entry 3 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,665.0826 F4 · kind: Restricted stock units acquired through deferral of compensation under the Company's Management Stock Purchase Program. Read SEC document
February 08, 2017 Filed Feb 10, 2017 18:23 UTC	BARD C R INC /NJ/ BCR · Entity 170698	GrantCommon Stock	3,194	$0.00	$0.00	Disclosure SEC source: 0001225208-17-002837 · doc4.xml · nonDerivative · entry 2 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,024.0826 F3 · price: Represents common shares acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated), 50% of which vest immediately and the remaining 50% vest in two equal annual installments on February 8, 2018 and February 8, 2019. Read SEC document
February 08, 2017 Filed Feb 10, 2017 18:23 UTC	BARD C R INC /NJ/ BCR · Entity 170698	GrantCommon Stock	8,223	$0.00	$0.00	Disclosure SEC source: 0001225208-17-002837 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,830.0826 F1 · price: Represents common shares acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F2 · balance_after: Includes 0.001 shares acquired under the Company's Employee Stock Purchase Plan from November 8, 2016 to February 6, 2017. Read SEC document
December 14, 2016 Filed Dec 16, 2016 15:35 UTC	BARD C R INC /NJ/ BCR · Entity 170698	GrantOption (Right to Buy) · Derivative	11,544	$0.00 Strike: $219.56	$0.00	Disclosure SEC source: 0001225208-16-043394 · doc4.xml · derivative · entry 1 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,544 Underlying: Common Stock · 11,544 shares Expires 2026-12-14 F1 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F2 · derivative.exercise_date: Options vest in four equal annual installments beginning on December 14, 2017. Read SEC document
December 12, 2016 Filed Dec 13, 2016 18:51 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionOption (Right to Buy) · Derivative	4,663	$0.00 Strike: $97.69	$0.00	Disclosure SEC source: 0001225208-16-043118 · doc4.xml · derivative · entry 14 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,663 shares Expires 2022-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F12 · derivative.exercise_date: Options fully vested and are currently exercisable. Read SEC document
December 12, 2016 Filed Dec 13, 2016 18:51 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionOption (Right to Buy) · Derivative	4,161	$0.00 Strike: $136.37	$0.00	Disclosure SEC source: 0001225208-16-043118 · doc4.xml · derivative · entry 13 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,161 Underlying: Common Stock · 4,161 shares Expires 2023-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F11 · derivative.exercise_date: Of this option grant 4,161 options vested on December 11, 2016 and the remaining options vest on December 11, 2017. Read SEC document
December 12, 2016 Filed Dec 13, 2016 18:51 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionOption (Right to Buy) · Derivative	3,767	$0.00 Strike: $168.87	$0.00	Disclosure SEC source: 0001225208-16-043118 · doc4.xml · derivative · entry 12 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,535 Underlying: Common Stock · 3,767 shares Expires 2024-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F10 · derivative.exercise_date: Of this option grant 3,767 options vested on December 10, 2016 and the remaining options vest in two annual installments beginning on December 10, 2017. Read SEC document
December 12, 2016 Filed Dec 13, 2016 18:51 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	5,621	$219.63	$1,234,532.36	Disclosure SEC source: 0001225208-16-043118 · doc4.xml · nonDerivative · entry 9 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,607.0816 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F6 · price: Represents the weighted average sales price for price increments ranging from $219.18 to $220.17. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
December 12, 2016 Filed Dec 13, 2016 18:51 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	4,167	$216.98	$904,157.33	Disclosure SEC source: 0001225208-16-043118 · doc4.xml · nonDerivative · entry 8 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,228.0816 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F5 · price: Represents the weighted average sales price for price increments ranging from $216.62 to $217.23. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
December 12, 2016 Filed Dec 13, 2016 18:51 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	1,977	$220.38	$435,685.33	Disclosure SEC source: 0001225208-16-043118 · doc4.xml · nonDerivative · entry 7 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,395.0816 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F4 · price: Represents the weighted average sales price for price increments ranging from $220.18 to $220.78. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
December 12, 2016 Filed Dec 13, 2016 18:51 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	826	$218.83	$180,757.46	Disclosure SEC source: 0001225208-16-043118 · doc4.xml · nonDerivative · entry 6 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,372.0816 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F3 · price: Represents the weighted average sales price for price increments ranging from $218.17 to $219.10. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
December 12, 2016 Filed Dec 13, 2016 18:51 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionCommon Stock	3,767	$168.87	$636,114.46	Disclosure SEC source: 0001225208-16-043118 · doc4.xml · nonDerivative · entry 5 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,198.0816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. Read SEC document
December 12, 2016 Filed Dec 13, 2016 18:51 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionCommon Stock	4,161	$136.37	$567,435.57	Disclosure SEC source: 0001225208-16-043118 · doc4.xml · nonDerivative · entry 4 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,431.0816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. Read SEC document
December 12, 2016 Filed Dec 13, 2016 18:51 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionCommon Stock	4,663	$97.69	$455,505.16	Disclosure SEC source: 0001225208-16-043118 · doc4.xml · nonDerivative · entry 3 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,270.0816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. Read SEC document
December 09, 2016 Filed Dec 13, 2016 18:51 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionOption (Right to Buy) · Derivative	3,292	$0.00 Strike: $186.43	$0.00	Disclosure SEC source: 0001225208-16-043118 · doc4.xml · derivative · entry 11 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,879 Underlying: Common Stock · 3,292 shares Expires 2025-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F9 · derivative.exercise_date: Of this option grant 3,292 options vested on December 9, 2016 and the remaining options vest in three annual installments beginning on December 9, 2017. Read SEC document
December 09, 2016 Filed Dec 13, 2016 18:51 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	3,292	$215.00	$707,780.00	Disclosure SEC source: 0001225208-16-043118 · doc4.xml · nonDerivative · entry 2 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,607.0816 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. Read SEC document
December 09, 2016 Filed Dec 13, 2016 18:51 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionCommon Stock	3,292	$186.43	$613,711.10	Disclosure SEC source: 0001225208-16-043118 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,899.0816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F2 · balance_after: Includes 0.0632 shares acquired under the Company's Dividend Reinvestment Plan from July 30, 2016 to November 4, 2016. Includes 0.001 shares acquired under the Company's Employee Stock Purchase Plan from August 2, 2016 to November 7, 2016. Read SEC document
September 06, 2016 Filed Sep 8, 2016 09:43 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionOption (Right to Buy) · Derivative	4,161	$0.00 Strike: $136.37	$0.00	Disclosure SEC source: 0001225208-16-039042 · doc4.xml · derivative · entry 7 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,322 Underlying: Common Stock · 4,161 shares Expires 2023-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F8 · derivative.exercise_date: Of this option grant 4,161 options vested on December 11, 2015 and the remaining options vest in two annual installments beginning on December 11, 2016. Read SEC document
September 06, 2016 Filed Sep 8, 2016 09:43 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionOption (Right to Buy) · Derivative	3,767	$0.00 Strike: $168.87	$0.00	Disclosure SEC source: 0001225208-16-039042 · doc4.xml · derivative · entry 6 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,302 Underlying: Common Stock · 3,767 shares Expires 2024-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Options granted under 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). F7 · derivative.exercise_date: Of this option grant 3,767 options vested on December 10, 2015 and the remaining options vest in three annual installments beginning on December 10, 2016. Read SEC document
September 06, 2016 Filed Sep 8, 2016 09:43 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	6,667	$220.95	$1,473,090.98	Disclosure SEC source: 0001225208-16-039042 · doc4.xml · nonDerivative · entry 4 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,607.0174 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F4 · price: Represents the weighted average sales price for price increments ranging from $220.42 to $221.39. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
September 06, 2016 Filed Sep 8, 2016 09:43 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	1,261	$221.64	$279,493.08	Disclosure SEC source: 0001225208-16-039042 · doc4.xml · nonDerivative · entry 3 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,274.0174 F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F3 · price: Represents the weighted average sales price for price increments ranging from $221.46 to $222.05. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document
September 06, 2016 Filed Sep 8, 2016 09:43 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionCommon Stock	3,767	$168.87	$636,114.46	Disclosure SEC source: 0001225208-16-039042 · doc4.xml · nonDerivative · entry 2 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,535.0174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. Read SEC document
September 06, 2016 Filed Sep 8, 2016 09:43 UTC	BARD C R INC /NJ/ BCR · Entity 170698	Exercise / conversionCommon Stock	4,161	$136.37	$567,435.57	Disclosure SEC source: 0001225208-16-039042 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,768.0174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan. F2 · balance_after: Includes 0.1202 shares acquired under the Company's Dividend Reinvestment Plan from February 6, 2016 to July 29, 2016. Includes 0.002 shares acquired under the Company's Employee Stock Purchase Plan from February 6, 2016 to August 1, 2016. Read SEC document
December 17, 2014 Filed May 11, 2017 11:46 UTC	BARD C R INC /NJ/ BCR · Entity 170698	SaleCommon Stock	2,741	$168.51	$461,877.14	Disclosure SEC source: 0001225208-17-009475 · doc4.xml · nonDerivative · entry 1 DeFord John A · CIK 0001403373 · Sr. VP Sci Tech and Clin Afrs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,995.5474 F1 · kind: Sales are pursuant to a previously disclosed 10b5-1 plan. F2 · price: Represents the weighted average sales price for price increments ranging from $167.82 to $168.68. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. F3 · balance_after: This transaction is being reported late and the amount in this column reflects the ownership immediately following this transaction. Subsequent Form 4s overstated the reporting person's direct ownership by 2,741 shares. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.